Gaithersburg, Maryland - December 23, 2004 - GlycoMimetics, Inc. (GMI), a privately held firm that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced the availability of electronic versions of the abstracts it presented at Glycobiology 2004, the largest annual gathering of glycobiologists world-wide.

The two abstracts describe the results of a series of experiments that demonstrate the use of carbohydrate mimics to inhibit inflammation and to inhibit the binding of a bacterial protein involved in P. aeruginosa infection. The experiments show it may be possible to develop novel therapies based on carbohydrate mimics for a broad range of diseases in humans.

"These results point to a new approach for tackling diseases of inflammation, " said GMI Chief Scientific Officer and Vice President John Magani, Ph.D., who performed the experiments and presented the abstracts. "They also show potential for a novel way of slowing or stopping the spread of bacteria, through inhibition of bacterial adhesion."

"The company's next steps will be to continue testing these and other compounds in additional models of disease, with a view to selecting compounds to move forward into pre-clinical development," said Rachel King, GMI's Chief Executive Officer.

GMI is a sponsor of this year's annual conference, which convened in Honolulu, Hawaii in November. This year's event marked a joint gathering of the Society for Glycobiology and The Japanese Society of Carbohydrate Research.

The two abstracts are entitled Pre-organization of the Bioactive Conformation of Glycomimetics for Lectins from Psuedomonas aeruginosa Enhances Activity into the Nanomolar Range, and Pan-Selectin Glycomimetic Inhibitors Inhibit Rolling and Neutrophil Migration in Mouse Models of Inflammation. The complete text of the two abstracts is available at:

<http://www.glycomimetics.com/library/abstracts.htm>

About GMI

GMI capitalizes on advances in the field of glycobiology by developing small molecule drugs that mimic the functions of certain carbohydrates. The company's initial focus is on therapeutics to treat inflammatory diseases and cancer. More information is available at the company's web site: http://www.glycomimetics.com.

# # #

09.02.05: GMI to Present New Data on Lead Compounds at International Symposium

08.15.05: Washington Business Journal - GlycoMimetics chief named to biotech institute's board

07.18.05: Washington Business Journal - GlycoMimetics CEO Named to bio group's board.

05.20.05: Windhover Start-up Magazine - Glycobiology's Second Wave

12.23.04: GMI Sponsors, Presents at Annual Glycobiology Conference

10.20.04: GMI Taps New VP to Head Clinical Development Effort

08.13.04: Baltimore Business Journal - Montgomery biotech GlycoMimetics taps into Baltimore VCs, state fund

08.05.04: GMI Secures $5.1-million in Series A Extension

03.26.04: Washington Business Journal: Some relief for biotech's financial headaches*

03.15.04: The Washington Post - GMI's research taps troublesome carbohydrates to combat disease *

01.07.04: Red Herring Magazine - Venture Capitol*

11.03.03: Washington Post - Venture Funding Dips in 3rd Quarter *

10.28.03: Ginsburg Memorial Symposium Announced

9.20.03: Recap Magazine - Glycobiology: Biotech's New Sweet Spot *

09.17.03: GMI Announces Key Adds to BOD

06.06.03: The Business Gazette - Rockville biotech company to put new financing to use *

05.22.03: GMI Closes $4.3M Seed Round

* The article will open in a new browser window.